Table 1.

Clinical association of TACC3 alterations in different cancers.

Type of cancer	Clinical association	Level of association	Reference
Breast cancer	High TACC3 – associated with stage, grade and worse overall survival	Protein & mRNA	[11,67]
Prostate cancer	High TACC3 – associated with metastasis status, tumor stage, total prostate–specific antigen (PSA) level, and Gleason score, and worse disease–free survival	mRNA, protein	[26,67]
NSCLC	High TACC3 – associated with differentiation, stage, grade, histologic type, smoking status and worse recurrence–free and overall survival	mRNA and protein	[87,88,96]
Osteosarcoma	High TACC3 – associated with worse metastasis–free survival	Protein	[90]
Gastric cancer	High TACC3 – associated with extracapsular extension of the tumor, tumor relapse and worse overall survival	mRNA, protein	[30,67]
Lymphoma	High TACC3 – associated with worse overall survival	Protein	[93]
Cervical cancer	High TACC3 – associated with tumor histological type, nerve invasion, differentiation, parametrium invasion, Ki-67, overall, disease–free and recurrence–free survival	Protein	[85]
Renal cancer	High TACC3 – associated with worse overall survival	mRNA	[89]
Esophageal squamous cell carcinoma	High TACC3 – associated with differentiation, lymphoid nodal status and worse overall survival	Protein	[91]
Head and neck cancer	High TACC3 – associated with worse overall survival	mRNA	[11]
Colorectal cancer	High TACC3 – associated with clinical stage, T classification and M classification, worse overall and disease–free survival	Protein	[29]
Glioma	High TACC3 – associated with worse overall survival	mRNA	[38]
	FGFR3-TACC3 – associated with better overall survival	mRNA	[104]
Bladder cancer	FGFR3-TACC3 – associated witha stronger risk of bladder cancer, especially for women	Gene	[95]
Hepatocellular cancer	High TACC3 – associated with worse overall and disease–free survival	Protein	[92]